呼吸道合胞病毒疫苗研制进展

被引:1
作者
侯伟
王丽
机构
[1] 西安医科大学第二附属医院儿科
[2] 富平县妇幼保健院儿科
关键词
呼吸道合胞病毒; 保护性抗原; 疫苗;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
呼吸道合胞病毒(RSV)疫苗研制已经历30多年,但至今仍无满意的疫苗可供预防RSV感染。近年来,RSV疫苗研制取得了较大的进展。减毒活疫苗、亚单位疫苗和基因重组疫苗的研制,为RSV感染的疫苗防治提供了可能性。
引用
收藏
页码:248 / 251
页数:4
相关论文
共 13 条
[1]  
A com paritsoh in chimpazees of the immunogenicity and efficacy of live attenuatrd respiratony syncytial virus temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Crowe JE Jr,collins PL.London WT,et al. Vaccine . 1993
[2]  
Immunity to any frequency of reinfectidn with respiratory syn cytial virus. Hall CB,Walsh EE.Long CE,et al. The Journal of Infectious Diseases . 1991
[3]  
Im munogenicity and safety of respiratiory syncytial virus subunit vaccine in seropositive children 18~36months old. Tristram DA,Welliver.BC,Moharc K,et al. The Journal of Infectious Diseases . 1993
[4]  
Tang YW,et ah Prim ing immunization determines T helper cytokine mR NA experession patterns in Lung of mice chal lenged with respiratory syncytial virus. Graham BS,Henderson GS. J Immunol . 1993
[5]  
Prospects for a respiratory syncytial virus vaccine. Mall CB. Science . 1994
[6]  
Im munogenicity and pathogenicity of triple tempera ture-sensitive modified respiratory syncytial virus in adult volunteers. Pringle CR.Filipiuk AH,Robinson BS,et al. Vaccine . 1994
[7]  
Satisfac torily attenuated and prtective mutant derived from a partially attenuation cold-passaged respira tory syncytial virus mutant by introduction of ad ditional attenuating mutations during chemical mutagensis. Crowe JE Jr.Bui FT,London WT,et al. Vaccine . 1994
[8]  
Enham ced pulmonary histopathology induced by respirato ry syncytial virus challenge of formalin-inactivat ed RSV-immunized BALB/C mice is abrog-ated by depletion of IL-4and IL-10. Connors M.Giese NA.kulkarni AB,et al. Journal of Virology . 1994
[9]  
A human respiratory syncytial virus primate model of en hanced pulmonary pathology induced with a for malin-inactivated RSV vaccine but not a recombi- nant FG suburit vaccine. kakuk TJ,soike K,Brideau RJ,et al. The Journal of Infectious Diseases . 1993
[10]  
Resistance to respiratory syncytial virus challenge induced by infection with a vaccinia virus recombi-nant expressing the RSV M2protein(Vac-M2) ismediated by CD8+T cell,white that induced by Vac-F or Vac-G recombinants is mediated by anti-bodied. Connors M,kukarni AB,Collins PL.et al. Journal of Virology . 1992